At BIO KOREA 2026 on April 29

Highlights 'Science, Differentiation, and IP' as Key Deal Criteria

Urges Ongoing Communication with Big Pharma

"It doesn't necessarily have to be first-in-class. As long as it has a differentiated profile, it can definitely be considered for investment."

Sridhar Gopal Mandapati, Executive Vice President of Global Business Development at AbbVie, said this during a media interview held on April 29, 2026, at COEX in Gangnam-gu, Seoul, as part of BIO KOREA 2026. Referring to the innovation shown by Korean biotech companies in ADCs (antibody-drug conjugates) and bispecific/trispecific antibodies, he emphasized the importance of differentiation over simply being the first. Mandapati, an expert with over 25 years of experience in global pharmaceutical business development, currently oversees AbbVie's late-stage pipeline acquisitions for all markets outside the United States. After working at AstraZeneca, he joined AbbVie, where he has led various mergers & acquisitions (M&A) and licensing agreements.


Sridhar Gopal Mandapati, Head of International Business Development at AbbVie, is speaking during a media interview at BIO KOREA 2026 held on the 29th at COEX in Gangnam-gu, Seoul. AbbVie

Sridhar Gopal Mandapati, Head of International Business Development at AbbVie, is speaking during a media interview at BIO KOREA 2026 held on the 29th at COEX in Gangnam-gu, Seoul. AbbVie

View original image

The company he serves, AbbVie, is a top global pharmaceutical corporation with annual sales exceeding 60 billion dollars. Its core areas include immunology, oncology, and neuroscience, and it has recently been expanding investments in obesity and pain management. Sixty-four percent of AbbVie's pipeline comes from external sources, and 60% of its revenue is also generated externally. AbbVie pursues external collaborations through various approaches, such as licensing-in, M&A, and early-stage technology partnerships. Mandapati stated, "Last year, we closed 17 deals, and we are currently working on about 250 collaborations," adding, "We manage all partnership products as meticulously as if they were our own in-house products."


He outlined three criteria for deal evaluation: science, differentiation, and intellectual property (IP). Mandapati explained, "The most important thing is investment in science," and added, "We look at what science is behind the product, what the concept is, and how it can translate into a future product." In particular, regarding differentiation, he said, "We consider how the current standard of care can be changed for patients and how competitive the product will be in the market." He concluded, "All these factors must be considered together to reach an evaluation decision."


Mandapati gave a positive assessment of the competitiveness of Korean biotech firms. He commented, "Korean companies possess all the right scientific attributes and have access to good materials," and added, "They have everything necessary to successfully develop products." Referring to the Innovator Award applicants introduced at BIO KOREA 2026, he said, "All the applicants demonstrated strong scientific characteristics." However, he also stressed the importance of collaboration, saying, "Biotech companies need to work well with pharmaceutical firms to move on to the next stage."



He also offered advice to biotech companies seeking partnerships. "A pharmaceutical company might say that now is not the right time for a relationship, but don't be discouraged—if you keep developing your data and keep communicating, a deal may materialize," he advised, encouraging active participation in conferences and partnering days to create touchpoints. AbbVie is preparing a partnering event this September. Mandapati added, "More teams will participate than before in order to seek out partnership opportunities."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing